Target Research Guide

TRPV1, explained simply with PubMed links

This page translates TRPV1 research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

96research sources

60evidence buckets

PubMedlinked references

What this page is

A plain-English research page about TRPV1. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 144

Traceable statements carried into the source table.

Human Evidence 0

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 65

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 6

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

TRPV1 has research behind it, but the bucket matters.

This page currently indexes 96 research sources across 60 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 29082315

Human evidence 0 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 29082315

Mechanisms 65 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 29082315

Safety and limits 6 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 29082315

Evidence Buckets

What the TRPV1 research is usually about

Jump to source-backed table

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms

TRPV1 appears in rows studying NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 12 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 29082315

TRPV1

TRPV1 appears in rows about TRPV1 mechanisms. It currently draws from 8 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30697147

Pain-related outcomes

TRPV1 appears in rows studying Pain-related outcomes. It currently draws from 6 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41680865

TRP channel activity or ionotropic cannabinoid target mechanisms

TRPV1 appears in rows about TRP channel activity or ionotropic cannabinoid target mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30697147

Receptor, target, metabolic, and pharmacology mechanisms

TRPV1 appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 27498155

TRPA1

TRPV1 appears in rows about TRPA1 mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 19070372

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (11)	PMID 29082315
TRPV1	Grouped source-backed rows focused on TRPV1, collapsed into one reader-facing bucket before the full source table.	Mapped evidence with interpretation limits: insufficient (8)	PMID 30697147
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: mechanistic or pharmacological (5), preclinical (1)	PMID 41680865
TRP channel activity or ionotropic cannabinoid target mechanisms	Grouped source-backed rows focused on TRP channel activity or ionotropic cannabinoid target mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)	PMID 30697147
Receptor, target, metabolic, and pharmacology mechanisms	Grouped source-backed rows focused on Receptor, target, metabolic, and pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (4)	PMID 27498155
TRPA1	Grouped source-backed rows focused on TRPA1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (3)	PMID 19070372
OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	PMID 19413995
TRPA1	Grouped source-backed rows focused on TRPA1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)	PMID 35483477

Safety Reading Notes

Read safety context beside the research guide.

The TRPV1 source set includes safety-context rows around NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 29082315

Mechanistic research summary: insufficient (1), mechanistic or pharmacological (11)

PubMed For Dummies Article

TRPV1 Evidence Review: the long-form source walk-through

Quick read

TRPV1 currently has 144 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 29082315
The evidence classes most visible in the row language are insufficient (70), mechanistic or pharmacological (66), and preclinical (8). PMID 41680865
The study-design language most visible in the row language is Animal study (59), Narrative or expert review (58), Cellular or in vitro study (19), and other mapped categories (4). PMID 41256665
The repeated topics are TRPV1 (18), NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o... (12), TRP channel activity or ionotropic cannabinoid target mechanisms (11), TRPA1 (11), and other mapped categories (92), which tells the reader where to start opening PubMed and DOI links. PMID 42139799

Start with the research question

TRPV1 is built from 144 source-backed evidence row(s) and 96 research source(s). The current evidence classes read as insufficient (70), mechanistic or pharmacological (66), and preclinical (8), and the study-design language most often reads as Animal study (59), Narrative or expert review (58), Cellular or in vitro study (19), and other mapped categories (4). PMID 29082315

The row-level question is not simply whether TRPV1 is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPV1 (18), NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, o... (12), TRP channel activity or ionotropic cannabinoid target mechanisms (11), TRPA1 (11), and other mapped categories (92). PMID 30697147

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 30633929

Preclinical evidence 6 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 36916438

Mechanistic evidence 65 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 31325449

Limits and uncertainty 76 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 30697147

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 33362478

Where this page has the most source density

The largest bucket surfaced for this page is NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPV1, which gives readers another way to see what the literature repeatedly circles. PMID 29082315

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 30697147

Bucket chapters: what the literature is circling

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms

12 research sources 12 rows (1131-1143) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (11)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 29082315

Evidence row 1131
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design:... PMID 29082315
Evidence row 1143
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study desi... PMID 17984664

TRPV1

8 research sources 8 rows (971-988) Mapped evidence with interpretation limits: insufficient (8)

TRPV1 appears in rows about TRPV1 mechanisms. It currently draws from 8 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30697147

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 30697147

Evidence row 971
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence row 988
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31695229

Pain-related outcomes

6 research sources 6 rows (684-699) Mechanistic and preclinical research summary: mechanistic or pharmacological (5), preclinical (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41680865

Evidence row 684
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41680865
Evidence row 699
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 20942863

TRP channel activity or ionotropic cannabinoid target mechanisms

6 research sources 6 rows (214-364) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 30697147

Evidence row 214
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mech... PMID 30697147
Evidence row 364
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome... PMID 21175579

Receptor, target, metabolic, and pharmacology mechanisms

5 research sources 5 rows (764-782) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (4)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 27498155

Evidence row 764
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 27498155
Evidence row 782
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 30074247

TRPA1

5 research sources 5 rows (1034-1042) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (3)

TRPV1 appears in rows about TRPA1 mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 19070372

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 19070372

Evidence row 1034
Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 19070372
Evidence row 1042
Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling... PMID 21645531

OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms

4 research sources 4 rows (1093-1097) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)

TRPV1 appears in rows studying OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 19413995

Evidence row 1093
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor... PMID 19413995
Evidence row 1097
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Anim... PMID 17449181

TRPA1

4 research sources 4 rows (1031-1046) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)

TRPV1 appears in rows about TRPA1 mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 35483477

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35483477

Evidence row 1031
CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477
Evidence row 1046
CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization,... PMID 32873774

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (65 row(s)), and safety/tolerability context (6 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 29082315

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 30697147

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 27498155
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 23924692
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 42212209

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 29082315

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 30697147

Source-reading checklist for TRPV1

Open the linked PubMed or DOI record. PMID 34384142
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 19833407
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 26698193
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 33155670
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 33168643

Source Notes

TRPV1 source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 35
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 75
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 76
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 116
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 30633929
Evidence class: preclinical; Study design: Animal study. Source: Preclinical safety and efficacy of cannabidivarin for early life seizures.
Evidence row 174
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 202
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 31325449
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.
Evidence row 214
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 215
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33362478
Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
Evidence row 216
THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 254
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Evidence row 256
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
Evidence row 280
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142
Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Evidence row 293
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 19833407
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.
Evidence row 357
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 358
Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33155670
Evidence class: insufficient; Study design: Narrative or expert review. Source: Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation.
Evidence row 359
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33168643
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacological Case for Cannabigerol.
Evidence row 360
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33629929
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Evidence row 361
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 362
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 363
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 18354058
Evidence class: insufficient; Study design: Animal study. Source: Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
Evidence row 364
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Evidence row 517
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 519
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 525
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 527
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 39275884
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.
Evidence row 557
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36497400
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.
Evidence row 558
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 568
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 570
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 607
CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 646
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 648
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 663
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 674
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40790027
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.
Evidence row 684
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 689
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 690
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 692
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 696
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41322279
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.
Evidence row 699
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 20942863
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.
Evidence row 704
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 711
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
Evidence row 713
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
Evidence row 721
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 752
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37305187
Evidence class: mechanistic or pharmacological; Study design: Case report or case series. Source: Hair Regrowth with Novel Hemp Extract: A Case Series.
Evidence row 764
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 765
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Evidence row 769
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
Evidence row 780
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21726418
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
Evidence row 782
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30074247
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Evidence row 784
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 808
THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 825
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31968549
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Evidence row 846
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16570099
Evidence class: insufficient; Study design: Narrative or expert review. Source: The pharmacology of cannabinoid receptors and their ligands: an overview.
Evidence row 927
THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 929
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35862111
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.
Evidence row 942
CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 41560741
Evidence class: insufficient; Study design: Narrative or expert review. Source: Epilepsy, neuroinflammation and cannabidiol What do we know thus far?
Evidence row 964
Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19413995
Evidence class: insufficient; Study design: Narrative or expert review. Source: N-acylethanolamines, anandamide and food intake.
Evidence row 966
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19285259
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
Evidence row 970
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30537148
Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
Evidence row 971
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 972
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 973
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 974
Cannabinoids modulates TRPV1; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40465624
Evidence class: preclinical; Study design: Animal study. Source: The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels.
Evidence row 975
Cannabinoids modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16109430
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid signalling.
Evidence row 976
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21309120
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and anxiety.
Evidence row 977
OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 17906678
Evidence class: insufficient; Study design: Narrative or expert review. Source: Novel cannabinoid receptors.
Evidence row 978
CBD modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 37199723
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
Evidence row 979
Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 26411767
Evidence class: insufficient; Study design: Narrative or expert review. Source: TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.
Evidence row 980
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 36222019
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling in microglia.
Evidence row 981
Cannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32738201
Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of TRPV1 channel function by natural products in the treatment of pain.
Evidence row 982
Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31408376
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The TRPV1 channel regulates glucose metabolism.
Evidence row 983
CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40684872
Evidence class: insufficient; Study design: Animal study. Source: Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.
Evidence row 984
THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31839498
Evidence class: insufficient; Study design: Narrative or expert review. Source: Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
Evidence row 985
THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30194563
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for the Treatment of Epilepsy: an Update.
Evidence row 986
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32091020
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
Evidence row 987
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 27179600
Evidence class: insufficient; Study design: Narrative or expert review. Source: Beyond Cannabis: Plants and the Endocannabinoid System.
Evidence row 988
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31695229
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.
Evidence row 989
THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 990
THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 991
CBD modulates TRPV2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 37199723
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
Evidence row 997
Cannabinoids modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 19070372
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
Evidence row 1001
CBD modulates TRPV2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 36747846
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
Evidence row 1004
THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1005
CBD modulates TRPV3; evidence class: insufficient (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 33362478
Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
Evidence row 1006
THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 1008
THC modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 21726418
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
Evidence row 1009
CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 37199723
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
Evidence row 1010
CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 36747846
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
Evidence row 1011
Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 20942817
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacogenetics of new analgesics.
Evidence row 1012
CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 28945920
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Human podocytes express functional thermosensitive TRPV channels.
Evidence row 1015
THC modulates TRPV3; evidence class: mechanistic or pharmacological (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 40141324
Evidence class: mechanistic or pharmacological. Source: The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids.
Evidence row 1016
THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1017
CBD modulates TRPV4; evidence class: insufficient (outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 33362478
Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
Evidence row 1019
THC modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 21726418
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
Evidence row 1020
Cannabinoids modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 19070372
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
Evidence row 1021
CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 28945920
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Human podocytes express functional thermosensitive TRPV channels.
Evidence row 1022
Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 32051870
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of TRPV4 activity by acetaminophen.
Evidence row 1024
Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 29470146
Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
Evidence row 1025
Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26990140
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Future Pharmacological Treatment of Bladder Dysfunction.
Evidence row 1026
Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 41802611
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.
Evidence row 1029
CBD modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 40006844
Evidence class: insufficient; Study design: Narrative or expert review. Source: Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.
Evidence row 1030
THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1031
CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1032
THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 1034
Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 19070372
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
Evidence row 1035
Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32051870
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of TRPV4 activity by acetaminophen.
Evidence row 1038
Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38219731
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.
Evidence row 1040
Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21727026
Evidence class: insufficient; Study design: Narrative or expert review. Source: G-protein coupled receptors regulating cough.
Evidence row 1042
Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21645531
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.
Evidence row 1043
CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32965166
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol activation of vagal afferent neurons requires TRPA1.
Evidence row 1044
CBD modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31446830
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Myrcene and terpene regulation of TRPV1.
Evidence row 1046
CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32873774
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.
Evidence row 1048
CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1049
THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 18354058
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
Evidence row 1050
THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Evidence row 1051
CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 1054
Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 19070372
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
Evidence row 1055
Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29470146
Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
Evidence row 1060
Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235
Evidence class: insufficient; Study design: Narrative or expert review. Source: Effects of opioids, cannabinoids, and vanilloids on body temperature.
Evidence row 1061
Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 17428469
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.
Evidence row 1063
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527
Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
Evidence row 1064
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27516570
Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism of endocannabinoids.
Evidence row 1093
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 19413995
Evidence class: insufficient; Study design: Narrative or expert review. Source: N-acylethanolamines, anandamide and food intake.
Evidence row 1094
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 19285259
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
Evidence row 1095
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 30537148
Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
Evidence row 1097
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 17449181
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Evidence row 1109
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 40563990
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.
Evidence row 1122
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 17445087
Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?
Evidence row 1131
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 29082315
Evidence class: insufficient; Study design: Narrative or expert review. Source: N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.
Evidence row 1132
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15245490
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.
Evidence row 1133
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17459108
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.
Evidence row 1135
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27189587
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Endovanilloids are potential activators of the trigeminovascular nocisensor complex.
Evidence row 1136
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20354008
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population.
Evidence row 1137
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15289293
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.
Evidence row 1138
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15006899
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.
Evidence row 1139
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25995819
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.
Evidence row 1140
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 28701511
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.
Evidence row 1141
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16760924
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
Evidence row 1142
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33568652
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
Evidence row 1143
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17984664
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.
Evidence row 1152
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15148262
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Evidence row 1166
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 19255745
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.
Evidence row 1184
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 16081411
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists.

Source Trail

Source-backed evidence table and references

96 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

TRPV1 is a cannabinoid-relevant target page. The current evidence ledger links it to 144 evidence row(s) from 96 source(s), mostly framed as insufficient (70), mechanistic or pharmacological (66), preclinical (8).

Identity

Canonical name: trpv1
Type: biological target
Subtype: trp_channel
Description: Not recorded

Evidence Snapshot

Evidence rows: 144
Sources: 96
Evidence classes: insufficient (70), mechanistic or pharmacological (66), preclinical (8)
Draft sections: mechanistic evidence (65), preclinical evidence (6), safety (6), uncertainty (67)

Key Draft Sections

Safety and tolerability: 6 evidence row(s).
Uncertainty and gaps: 67 evidence row(s).
Preclinical evidence: 6 evidence row(s).
Mechanistic evidence: 65 evidence row(s).

Ligands And Modulators

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
Anandamide	studied for	anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (1063-1064)
Anandamide	modulates	GPR119	Mapped evidence with interpretation limits: insufficient (1)	1	964
Anandamide	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	979
Cannabinoids	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	358
Cannabinoids	modulates	TRPA1	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (3)	5	5 rows (1034-1042)
Cannabinoids	modulates	TRPM8	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (1054-1060)
Cannabinoids	modulates	TRPV1	Preclinical research summary: insufficient (2), preclinical (1)	3	3 rows (974-981)
Cannabinoids	modulates	TRPV2	Mapped evidence with interpretation limits: insufficient (1)	1	997
Cannabinoids	modulates	TRPV3	Mapped evidence with interpretation limits: insufficient (1)	1	1011
Cannabinoids	modulates	TRPV4	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)	4	4 rows (1020-1026)
CBC	studied for	Inflammation-related outcomes	Mechanistic research summary: mechanistic or pharmacological (3)	3	3 rows (35-76)
CBC	studied for	neurobehavioral, mood, neural stem cell, or neurogenesis outcomes	Mechanistic research summary: mechanistic or pharmacological (1)	1	721
CBC	studied for	Pain-related outcomes	Mechanistic and preclinical research summary: mechanistic or pharmacological (5), preclinical (1)	6	6 rows (684-699)
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (663-674)
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Preclinical research summary: insufficient (1), preclinical (1)	2	2 rows (646-648)
CBC	studied for	Skin and inflammatory dermatology	Mechanistic and preclinical research summary: mechanistic or pharmacological (2), preclinical (1)	3	3 rows (704-713)
CBD	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (1)	1	942
CBD	modulates	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (254-256)
CBD	studied for	receptor, target, or pharmacology mechanisms	Preclinical research summary: preclinical (1)	1	280
CBD	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (215-361)
CBD	modulates	TRPA1	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)	4	4 rows (1031-1046)
CBD	modulates	TRPM8	Mapped evidence with interpretation limits: insufficient (1)	1	1048
CBD	modulates	TRPV1	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (978-983)
CBD	modulates	TRPV2	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (991-1001)
CBD	modulates	TRPV3	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (3)	4	4 rows (1005-1012)
CBD	modulates	TRPV4	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (1017-1029)
CBDV	studied for	Seizure and neurodevelopmental outcomes	Preclinical research summary: preclinical (1)	1	116
CBG	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (568-570)
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Preclinical research summary: preclinical (1)	1	174
CBG	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (557-558)
CBG	studied for	Skin and inflammatory dermatology	Preclinical research summary: preclinical (1)	1	607
CBG	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (1)	1	1051
CBN	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (517-519)
CBN	studied for	Skin and inflammatory dermatology	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (525-527)
Endocannabinoids	modulates	CB1	Mapped evidence with interpretation limits: insufficient (1)	1	846
Endocannabinoids	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Mechanistic research summary: mechanistic or pharmacological (1)	1	202
Endocannabinoids	modulates	GPR119	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (966-970)
Endocannabinoids	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (1)	1	929
Endocannabinoids	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (1)	1	1061
Endocannabinoids	modulates	TRPV1	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (980-987)
Endocannabinoids	modulates	TRPV4	Mapped evidence with interpretation limits: insufficient (1)	1	1025
LEA	studied for	LEA biology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	1184
NADA	studied for	NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (11)	12	12 rows (1131-1143)
Noladin ether	studied for	noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	1152
OEA	studied for	OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (1093-1097)
OEA	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	977
Oleamide	studied for	oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	1122
PEA	studied for	PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	1109
THC	modulates	CB1	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (808-825)
THC	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Mapped evidence with interpretation limits: insufficient (1)	1	293
THC	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (1)	1	927
THC	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)	6	6 rows (214-364)
THC	modulates	TRPA1	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (1030-1032)
THC	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (1049-1050)
THC	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (8)	8	8 rows (971-988)
THC	modulates	TRPV2	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (989-990)
THC	modulates	TRPV3	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)	3	3 rows (1004-1015)
THC	modulates	TRPV4	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (1016-1019)
THCV	studied for	Inflammation-related outcomes	Mechanistic research summary: mechanistic or pharmacological (1)	1	784
THCV	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (4)	5	5 rows (764-782)
...	...	...	...	...	4 more bucket(s)

Source-Backed Evidence Table

Evidence Row	Statement	Source
35	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
75	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
76	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
116	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	Preclinical safety and efficacy of cannabidivarin for early life seizures.PubMed 30633929 DOI 10.1016/j.neuropharm.2019.01.002
174	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
202	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
214	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
215	CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.PubMed 33362478 DOI 10.3389/fncel.2020.615811
216	THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
254	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
256	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
280	CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
293	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.PubMed 19833407 DOI 10.1016/j.imbio.2009.09.007
357	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
358	Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation.PubMed 33155670 DOI 10.1111/bph.15310
359	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	The Pharmacological Case for Cannabigerol.PubMed 33168643 DOI 10.1124/jpet.120.000340
360	CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.PubMed 33629929 DOI 10.1080/15548627.2021.1885203
361	CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
362	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
363	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.PubMed 18354058 DOI 10.1124/jpet.107.134809
364	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
517	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
519	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
525	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
527	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.PubMed 39275884 DOI 10.1002/biof.2122
557	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
558	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
568	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
570	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
607	CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
646	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
648	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
663	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
674	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
684	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
689	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
690	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
692	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
696	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.PubMed 41322279 DOI 10.2147/jpr.s547613
699	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.PubMed 20942863 DOI 10.1111/j.1476-5381.2010.01063.x
704	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
711	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
713	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
721	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
752	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
764	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
765	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
769	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
780	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
782	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.PubMed 30074247 DOI 10.1111/bph.14460
784	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
808	THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
825	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
846	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
927	THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
929	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
942	CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Epilepsy, neuroinflammation and cannabidiol What do we know thus far?PubMed 41560741 DOI 10.3389/fphar.2025.1749260
964	Anandamide modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	N-acylethanolamines, anandamide and food intake.PubMed 19413995 DOI 10.1016/j.bcp.2009.04.024
966	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
970	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.PubMed 30537148 DOI 10.1002/jcp.27913
971	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
972	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
973	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
974	Cannabinoids modulates TRPV1; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels.PubMed 40465624 DOI 10.1073/pnas.2413811122
975	Cannabinoids modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid signalling.PubMed 16109430 DOI 10.1016/j.lfs.2005.05.055
976	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids and anxiety.PubMed 21309120 DOI 10.1007/7854_2009_16
977	OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
978	CBD modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 37199723 DOI 10.7554/elife.86166
979	Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.PubMed 26411767 DOI 10.2174/1570159x13666150216222543
980	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
981	Cannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Modulation of TRPV1 channel function by natural products in the treatment of pain.PubMed 32738201 DOI 10.1016/j.cbi.2020.109178
982	Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
983	CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.PubMed 40684872 DOI 10.1016/j.pnpbp.2025.111456
984	THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.PubMed 31839498 DOI 10.1016/j.yebeh.2019.106832
985	THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabis for the Treatment of Epilepsy: an Update.PubMed 30194563 DOI 10.1007/s11910-018-0882-y
986	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.PubMed 32091020 DOI 10.24875/gmm.m20000334
987	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Beyond Cannabis: Plants and the Endocannabinoid System.PubMed 27179600 DOI 10.1016/j.tips.2016.04.005
988	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.PubMed 31695229 DOI 10.24875/gmm.19004881
989	THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
990	THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
991	CBD modulates TRPV2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 37199723 DOI 10.7554/elife.86166
997	Cannabinoids modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.PubMed 19070372 DOI 10.1016/j.tips.2008.10.008
1001	CBD modulates TRPV2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 36747846 DOI 10.1101/2023.01.27.525817
1004	THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1005	CBD modulates TRPV3; evidence class: insufficient (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.PubMed 33362478 DOI 10.3389/fncel.2020.615811
1006	THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
1008	THC modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
1009	CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 37199723 DOI 10.7554/elife.86166
1010	CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 36747846 DOI 10.1101/2023.01.27.525817
1011	Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Pharmacogenetics of new analgesics.PubMed 20942817 DOI 10.1111/j.1476-5381.2010.01074.x
1012	CBD modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Human podocytes express functional thermosensitive TRPV channels.PubMed 28945920 DOI 10.1111/bph.14052
1015	THC modulates TRPV3; evidence class: mechanistic or pharmacological (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids.PubMed 40141324 DOI 10.3390/ijms26062682
1016	THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1017	CBD modulates TRPV4; evidence class: insufficient (outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.PubMed 33362478 DOI 10.3389/fncel.2020.615811
1019	THC modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
1020	Cannabinoids modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.PubMed 19070372 DOI 10.1016/j.tips.2008.10.008
1021	CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Human podocytes express functional thermosensitive TRPV channels.PubMed 28945920 DOI 10.1111/bph.14052
1022	Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Modification of TRPV4 activity by acetaminophen.PubMed 32051870 DOI 10.1016/j.heliyon.2020.e03301
1024	Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
1025	Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Potential Future Pharmacological Treatment of Bladder Dysfunction.PubMed 26990140 DOI 10.1111/bcpt.12577
1026	Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
1029	CBD modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.PubMed 40006844 DOI 10.3390/plants14040585
1030	THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1031	CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1032	THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
1034	Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.PubMed 19070372 DOI 10.1016/j.tips.2008.10.008
1035	Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Modification of TRPV4 activity by acetaminophen.PubMed 32051870 DOI 10.1016/j.heliyon.2020.e03301
1038	Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.PubMed 38219731 DOI 10.1055/a-2244-8855
1040	Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	G-protein coupled receptors regulating cough.PubMed 21727026 DOI 10.1016/j.coph.2011.06.005
1042	Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.PubMed 21645531 DOI 10.1016/j.neuropharm.2011.05.024
1043	CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabidiol activation of vagal afferent neurons requires TRPA1.PubMed 32965166 DOI 10.1152/jn.00128.2020
1044	CBD modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Myrcene and terpene regulation of TRPV1.PubMed 31446830 DOI 10.1080/19336950.2019.1654347
1046	CBD modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.PubMed 32873774 DOI 10.1038/s41419-020-02892-1
1048	CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1049	THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.PubMed 18354058 DOI 10.1124/jpet.107.134809
1050	THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
1051	CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
1054	Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.PubMed 19070372 DOI 10.1016/j.tips.2008.10.008
1055	Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
1060	Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Effects of opioids, cannabinoids, and vanilloids on body temperature.PubMed 21622235 DOI 10.2741/190
1061	Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.PubMed 17428469 DOI 10.1016/j.yexcr.2007.01.008
1063	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
1064	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
1093	OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms).	N-acylethanolamines, anandamide and food intake.PubMed 19413995 DOI 10.1016/j.bcp.2009.04.024
1094	OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms).	Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
1095	OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms).	Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.PubMed 30537148 DOI 10.1002/jcp.27913
1097	OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms).	Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.PubMed 17449181 DOI 10.1016/j.pain.2007.03.008
1109	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
1122	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?PubMed 17445087 DOI 10.1111/j.1527-3466.2007.00004.x
1131	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.PubMed 29082315 DOI 10.1089/can.2017.0015
1132	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.PubMed 15245490 DOI 10.1111/j.1460-9568.2004.03481.x
1133	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.PubMed 17459108 DOI 10.1111/j.1460-9568.2007.05521.x
1135	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endovanilloids are potential activators of the trigeminovascular nocisensor complex.PubMed 27189587 DOI 10.1186/s10194-016-0644-7
1136	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population.PubMed 20354008 DOI 10.1093/bja/aeq067
1137	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.PubMed 15289293 DOI 10.1038/sj.bjp.0705924
1138	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.PubMed 15006899 DOI 10.1038/sj.bjp.0705711
1139	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.PubMed 25995819 DOI 10.4062/biomolther.2014.137
1140	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.PubMed 28701511 DOI 10.4049/jimmunol.1602151
1141	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.PubMed 16760924 DOI 10.1038/sj.npp.1301118
1142	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
1143	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.PubMed 17984664 DOI 10.1097/hjh.0b013e3282efd1bf
1152	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
1166	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.PubMed 19255745 DOI 10.1007/s00210-009-0406-z
1184	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists.PubMed 16081411 DOI 10.1074/jbc.m507429200

Anandamide
CB1
CBC
CBD
CBDV
CBG
CBN
Cannabinoids
Endocannabinoids
GPR119
GPR55
Inflammation-related outcomes
LEA
NADA
Noladin ether
OEA
Oleamide
PEA
Pain-related outcomes
Seizure and neurodevelopmental outcomes

References

Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
Preclinical safety and efficacy of cannabidivarin for early life seizures.PubMed 30633929 DOI 10.1016/j.neuropharm.2019.01.002
The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.PubMed 33362478 DOI 10.3389/fncel.2020.615811
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.PubMed 19833407 DOI 10.1016/j.imbio.2009.09.007
An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation.PubMed 33155670 DOI 10.1111/bph.15310
The Pharmacological Case for Cannabigerol.PubMed 33168643 DOI 10.1124/jpet.120.000340
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.PubMed 33629929 DOI 10.1080/15548627.2021.1885203
Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.PubMed 18354058 DOI 10.1124/jpet.107.134809
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.PubMed 39275884 DOI 10.1002/biof.2122
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.PubMed 41322279 DOI 10.2147/jpr.s547613
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.PubMed 20942863 DOI 10.1111/j.1476-5381.2010.01063.x
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.PubMed 30074247 DOI 10.1111/bph.14460
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
Epilepsy, neuroinflammation and cannabidiol What do we know thus far?PubMed 41560741 DOI 10.3389/fphar.2025.1749260
N-acylethanolamines, anandamide and food intake.PubMed 19413995 DOI 10.1016/j.bcp.2009.04.024
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.PubMed 30537148 DOI 10.1002/jcp.27913
The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels.PubMed 40465624 DOI 10.1073/pnas.2413811122
Cannabinoid signalling.PubMed 16109430 DOI 10.1016/j.lfs.2005.05.055
Cannabinoids and anxiety.PubMed 21309120 DOI 10.1007/7854_2009_16
Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 37199723 DOI 10.7554/elife.86166
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.PubMed 26411767 DOI 10.2174/1570159x13666150216222543
Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
Modulation of TRPV1 channel function by natural products in the treatment of pain.PubMed 32738201 DOI 10.1016/j.cbi.2020.109178
The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.PubMed 40684872 DOI 10.1016/j.pnpbp.2025.111456
Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.PubMed 31839498 DOI 10.1016/j.yebeh.2019.106832
Cannabis for the Treatment of Epilepsy: an Update.PubMed 30194563 DOI 10.1007/s11910-018-0882-y
Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.PubMed 32091020 DOI 10.24875/gmm.m20000334
Beyond Cannabis: Plants and the Endocannabinoid System.PubMed 27179600 DOI 10.1016/j.tips.2016.04.005
Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.PubMed 31695229 DOI 10.24875/gmm.19004881
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.PubMed 19070372 DOI 10.1016/j.tips.2008.10.008
Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.PubMed 36747846 DOI 10.1101/2023.01.27.525817
Pharmacogenetics of new analgesics.PubMed 20942817 DOI 10.1111/j.1476-5381.2010.01074.x
Human podocytes express functional thermosensitive TRPV channels.PubMed 28945920 DOI 10.1111/bph.14052
The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids.PubMed 40141324 DOI 10.3390/ijms26062682
Modification of TRPV4 activity by acetaminophen.PubMed 32051870 DOI 10.1016/j.heliyon.2020.e03301
Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
Potential Future Pharmacological Treatment of Bladder Dysfunction.PubMed 26990140 DOI 10.1111/bcpt.12577
Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.PubMed 40006844 DOI 10.3390/plants14040585
Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.PubMed 38219731 DOI 10.1055/a-2244-8855
G-protein coupled receptors regulating cough.PubMed 21727026 DOI 10.1016/j.coph.2011.06.005
Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.PubMed 21645531 DOI 10.1016/j.neuropharm.2011.05.024
Cannabidiol activation of vagal afferent neurons requires TRPA1.PubMed 32965166 DOI 10.1152/jn.00128.2020
Myrcene and terpene regulation of TRPV1.PubMed 31446830 DOI 10.1080/19336950.2019.1654347
Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts.PubMed 32873774 DOI 10.1038/s41419-020-02892-1
Effects of opioids, cannabinoids, and vanilloids on body temperature.PubMed 21622235 DOI 10.2741/190
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.PubMed 17428469 DOI 10.1016/j.yexcr.2007.01.008
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.PubMed 17449181 DOI 10.1016/j.pain.2007.03.008
Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?PubMed 17445087 DOI 10.1111/j.1527-3466.2007.00004.x
N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.PubMed 29082315 DOI 10.1089/can.2017.0015
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.PubMed 15245490 DOI 10.1111/j.1460-9568.2004.03481.x
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.PubMed 17459108 DOI 10.1111/j.1460-9568.2007.05521.x
Endovanilloids are potential activators of the trigeminovascular nocisensor complex.PubMed 27189587 DOI 10.1186/s10194-016-0644-7
Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population.PubMed 20354008 DOI 10.1093/bja/aeq067
Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.PubMed 15289293 DOI 10.1038/sj.bjp.0705924
Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.PubMed 15006899 DOI 10.1038/sj.bjp.0705711
A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.PubMed 25995819 DOI 10.4062/biomolther.2014.137
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.PubMed 28701511 DOI 10.4049/jimmunol.1602151
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.PubMed 16760924 DOI 10.1038/sj.npp.1301118
Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.PubMed 17984664 DOI 10.1097/hjh.0b013e3282efd1bf
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.PubMed 19255745 DOI 10.1007/s00210-009-0406-z
Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists.PubMed 16081411 DOI 10.1074/jbc.m507429200

TRPV1 has research behind it, but the bucket matters.

What the TRPV1 research is usually about

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms

TRPV1

Pain-related outcomes

TRP channel activity or ionotropic cannabinoid target mechanisms

Receptor, target, metabolic, and pharmacology mechanisms

TRPA1

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

TRPV1 Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms

TRPV1

Pain-related outcomes

TRP channel activity or ionotropic cannabinoid target mechanisms

Receptor, target, metabolic, and pharmacology mechanisms

TRPA1

OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms

TRPA1

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for TRPV1

TRPV1 source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Ligands And Modulators

Source-Backed Evidence Table

Related Pages

References